Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.51 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.47 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197036 | 1.00 | CYP17A1 (0.54) | CYP17A1AAK1HDAC2HDAC1KCNQ4 | |
| SCHEMBL20163070 | 0.91 | ABCB1 (0.56) | CYP17A1AAK1HDAC2HDAC1KCNQ4 | |
| SCHEMBL25216132 | 0.89 | CYP17A1 (0.54) | CYP17A1AAK1HDAC2HDAC1KCNQ4 | |
| SCHEMBL3786645 | 0.89 | AAK1 (0.53) | CYP17A1AAK1HDAC2HDAC1ABCB1 | |
| SCHEMBL197145 | 0.89 | HDAC1 (0.55) | CYP17A1AAK1HDAC2HDAC1KCNQ4 | |
| SCHEMBL29581478 | 0.89 | HDAC1 (0.55) | CYP17A1AAK1HDAC2HDAC1KCNQ4 | |
| SCHEMBL5868895 | 0.88 | AAK1 (0.48) | CYP17A1AAK1HDAC2HDAC1KCNQ4 | |
| SCHEMBL30118376 | 0.88 | AAK1 (0.48) | CYP17A1AAK1HDAC2HDAC1KCNQ4 | |
| SCHEMBL5869075 | 0.88 | AAK1 (0.52) | CYP17A1AAK1ABCB1ABCC1MAP4K4 | |
| SCHEMBL5868802 | 0.88 | ABCB1 (0.54) | CYP17A1AAK1HDAC2HDAC1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103694-A1 | HDAC INHIBITOR, AND PREPARATION AND USE THEREOF | 赛岚(杭州)生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023102162-A1 | TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220281833-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | CYP17A1 1970/4885AAK1 2325/4885HDAC2 2/4885 |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | CYP17A1 1294/4885AAK1 2510/4885HDAC2 9/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | CYP17A1 950/4885AAK1 1755/4885HDAC2 1/4885 |
| US-20220281833-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | CYP17A1 2915/4885AAK1 1492/4885HDAC2 2/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | CYP17A1 657/4885AAK1 3018/4885HDAC2 8/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | CYP17A1 657/4885AAK1 3018/4885HDAC2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.